Overexpression of the GLUT1-targeting miR-218 increased chemosensitivity of bladder cancer cells to cisplatin [86], while miR-153 enhanced sensitivity against arsenious acid in chronic myeloid leukemia (CML) [126]. This evidence concerns the gene SLC2A1 and chronic myelogenous leukemia, BCR-ABL1 positive.